Tarsus Pharmaceuticals prices $125M primary offering at $44.50/share; net proceeds $117.1M

Filed March 13, 2025 · ~1 min read

Key Changes

• high

  Tarsus is selling 2,808,988 shares at $44.50 each, raising $125.0M gross; net proceeds to the company are $117.1M.

  The Offering verify on EDGAR →
• high

  Proceeds will fund XDEMVY commercialization, pipeline development (TP-04, TP-05), and general corporate purposes.

  Use of Proceeds verify on EDGAR →
• high

  New investors face immediate dilution of $36.40 per share, as the offering price far exceeds net tangible book value.

  Dilution verify on EDGAR →